---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-052074"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T07:54:03.980069+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rezolute to present Phase 2 RIZE overnight hypoglycemia data at PES Annual Meeting

## Summary
- Dr. Paul Thornton will present poster analyzing overnight hypoglycemia in congenital HI patients on May 4, 2024 at PES meeting.
- Sub-analyses from Phase 2 RIZE study highlight RZ358 benefits during overnight fasting using CGM metrics.
- Previously reported results showed up to ~90% reduction in hypoglycemia events and time at top doses.
- Phase 3 study of RZ358 for congenital hyperinsulinism is currently underway.

## SEC filing metadata
- accession: 0001104659-24-052074
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465924052074/0001104659-24-052074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465924052074/tm2412530d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-052074
- JSON: https://secwatch.observer/filing/0001104659-24-052074.json
- Plain text: https://secwatch.observer/filing/0001104659-24-052074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.